Alzheimer's Disease
Conditions
Interventions
Product Name: SRA-333
Product Code: SRA-333
Pharmaceutical Form: Tablet
INN or Proposed INN: N/A
CAS Number: N/A
Current Sponsor code: WAY-161333 HCL
Other descriptive name: SRA-333
Concentration unit
Sponsors
Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of probable AD according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria. 2. Men and postmenopausal or surgically sterile women aged 50 years or older. Postmenopausal women must have had at least 12 months of spontaneous amenorrhea. Surgically sterile women are defined as those who have had a hysterectomy, bilateral ovariectomy (oophorectomy), or bilateral tubal ligation. 3. Mini-Mental State Examination (MMSE) score of 12 to 26. 4. Rosen Modified Hachinski Ischemic score ==65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Significant neurological disease other than AD that may affect cognition (eg, epilepsy, Parkinson disease) or ability to complete the study. 2. Current diagnosis of a major depressive disorder or other major psychiatric symptoms included in psychiatric disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV), criteria. 3. Current clinically significant systemic illness that, in the judgment of the investigator, is likely to deteriorate or affect the patient’s safety, influence cognitive assessment, or ability to complete the study. 4. History of seizure, except a febrile childhood febrile seizure. 5. History of clinically evident stroke or clinically significant carotid or vertebrobasilar stenosis or plaque. 6. Myocardial infarction within the last 3 months. 7. History of cancer within the last 5 years, with the exception of nonmetastatic basal and/or squamous cell carcinoma of the skin 8. History of alcohol or drug dependence within the last 1 year. 9. Hamilton Psychiatric Rating Scale for Depression, 21 items (HAM-D21) score > 17. 10. Any clinically significant deviation in physical examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that in the judgment of the investigator, is likely to deteriorate or affect the patient’s safety or ability to complete the study. 11. History of any clinically important multiple drug allergies, that will compromise the patient’s safety during the study. 12. Use of medications for the treatment of cognitive enhancements, including memantine, and the use of cholinesterase inhibitors within 3 months the baseline visit and any history of intolerance or lack of response to cholinesterase inhibitors. 13. Any use of investigational drugs or procedures within 30 days of baseline visit. 14. Use of experimental medications for AD within 30 days before baseline visit. 15. Current use of anticonvulsant, anti Parkinson, antipsychotic, antidepressant medication and buspirone within 30 days of baseline visit (except for fluoxetine, which is excluded within 60 days of baseline). 16. Regular use of narcotic medications within 30 days of baseline visit. 17. Treatment with strong inhibitors of the cytochrome P450 3A4 isoenzyme system (i.e. ketoconazole, itraconazole, erythromycin, clarithromycin) within 1 week of baseline visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective is to determine the safety, tolerability, and efficacy of 3 doses of SRA-333 in patients with mild to moderate AD over 12 weeks.;Secondary Objective: Secondary objectives are to estimate comparative safety, tolerability and efficacy versus donepezil over a 12-week period in patients with AD and to measure the responsiveness of patient and caregiver-reported outcomes instruments.;Primary end point(s): The primary endpoints will be the change from baseline in ADAS-Cog total score and ADCS-CGIC at week 12. | — |
Countries
Finland, Sweden
Outcome results
None listed